Share
PDFLaw, ethics and medicine
Paper
Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
Other content recommended for you
- Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
- Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
- Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
- Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
- Children’s views on taking medicines and participating in clinical trials
- Nusinersen for SMA: expanded access programme
- Engaging African ancestry participants in SLE clinical trials
- Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of ‘compassionate therapies’ in times of catastrophic pandemics
- Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
- Expanded access: growing importance to public health